Patents by Inventor Marlene L. Cohen

Marlene L. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-HT.sub.4 agonists and antagonists
    Patent number: 6117882
    Abstract: Compounds of formula I: ##STR1## are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: September 12, 2000
    Assignee: Eli Lilly and Company
    Inventors: John M. Schaus, Marlene L. Cohen, Dennis C. Thompson
  • 5-HT.sub.4 agonists and antagonists
    Patent number: 6069152
    Abstract: Compounds of formula I: ##STR1## are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.
    Type: Grant
    Filed: October 7, 1997
    Date of Patent: May 30, 2000
    Assignee: Eli Lilly and Company
    Inventors: John M. Schaus, Marlene L. Cohen, Dennis C. Thompson
  • Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT.sub.7 receptor
    Patent number: 5880134
    Abstract: The present invention provides a method for altering mammalian central and peripheral physiological and pathological functioning which is mediated by serotonin binding to the 5-HT.sub.7 receptor. Specifically, the invention provides a method for antagonizing serotonin binding to the 5-HT.sub.7 receptor.
    Type: Grant
    Filed: October 7, 1997
    Date of Patent: March 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: Marlene L Cohen, Daniel J Cushing
  • Calcium channel antagonists
    Patent number: 5840747
    Abstract: A method for antagonizing or blocking calcium channels in vascular tissue, comprising administering to an animal in need thereof a pharmaceutically-effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.4 alkyl, --CO--(C.sub.1 -C.sub.6 alkyl), or --CH.sub.2 Ar, --CO--Ar, wherein Ar is phenyl or substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventor: Marlene L. Cohen
  • Indazolecarboxamides
    Patent number: 5817676
    Abstract: Indazolecarboxamides are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: John T. Catlow, Marlene L. Cohen, Michael O. Martinelli, John M. Schaus, Steven Swanson, Dennis C. Thompson, Thomas M. Wilson
  • Indazolecarboxamides
    Patent number: 5798367
    Abstract: Indazolecarboxamides are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: August 25, 1998
    Assignee: Eli Lilly and Company
    Inventors: John T. Catlow, Marlene L. Cohen, Michael J. Martinelli, John M. Schaus, Steven Swanson, Dennis C. Thompson, Thomas M. Wilson
  • Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
    Patent number: 5744482
    Abstract: Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: April 28, 1998
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, Kirk W. Johnson, Lee A. Phebus
  • Substituted cyclo or bicycloalkylamides of (8.beta.)-6-(substituted) ergolines
    Patent number: 5739146
    Abstract: The present invention provides (8.beta.)-N-substituted cyclo or bicycloalkyl-6-(substituted)-ergoline-8-carboxamides useful for occupying 5HT.sub.2 or 5HT.sub.1.sbsb.c receptors in mammals. The invention also provides methods for treating a variety of disorders and conditions related to or affecting these receptors as well as pharmaceutical formulations of the compounds of the invention.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: April 14, 1998
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, David W. Robertson
  • Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor mediated conditions
    Patent number: 5736544
    Abstract: The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: April 7, 1998
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Marlene L. Cohen, Jaswant S. Gidda, David L. G. Nelson
  • 5-HT.sub.1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
    Patent number: 5698571
    Abstract: The present invention provides a method for the treatment of migraine with compounds or compositions that are selective agonists of 5-HT.sub.1F receptors relative to other serotonin receptors that produce unwanted effects like vasoconstriction. The neurogenic meningeal extravasation that leads to the pain of migraine is inhibited.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: December 16, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Marlene L. Cohen, Kirk W. Johnson, Lee A. Phebus, Theresa Branchek
  • Method for treating 5HT.sub.2B receptor related conditions
    Patent number: 5688807
    Abstract: The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: November 18, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Marlene L. Cohen, Jaswant S. Gidda, David L. G. Nelson
  • Method of blocking human 5-hydroxytryptamine-2 receptors
    Patent number: 5674875
    Abstract: N-unsubstituted ergolines specifically bind to human 5-HT.sub.2 receptors, and are thus useful in treating diseases such as depression, hypertension and migraine.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: October 7, 1997
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, David L. G. Nelson
  • Specific 5-HT3 antagonists
    Patent number: 5563148
    Abstract: This invention provides bicyclic carboxylic esters and amides, their pharmaceutical formulations, and a method for their use in treating migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in mammals.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, William B. Lacefield, David W. Robertson
  • Substituted cyclo or bicycloalkylamides of (8.beta.)-6-(substituted) ergolines
    Patent number: 5441961
    Abstract: The present invention provides (8.beta.)-N-substituted cyclo or bicycloalkyl-6-(substituted)-ergoline-8-carboxamides useful for occupying 5HT.sub.2 or 5HT.sub.1c receptors in mammals. The invention also provides methods for treating a variety of disorders and conditions related to or affecting these receptors as well as pharmaceutical formulations of the compounds of the invention.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, David W. Robertson
  • Intermediates for specific 5-HT3 antagonists
    Patent number: 5442078
    Abstract: This invention provides bicyclic carboxylic esters and amides, their pharmaceutical formulations, and a method for their use in treating migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in mammals.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, William B. Lacefield, David W. Robertson
  • Specific 5-HT.sub.3 antagonists
    Patent number: 5364863
    Abstract: This invention provides bicyclic carboxylic esters and amides, their pharmaceutical formulations, and a method for their use in treating migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in mammals.
    Type: Grant
    Filed: April 26, 1993
    Date of Patent: November 15, 1994
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, William B. Lacefield, David W. Robertson
  • N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
    Patent number: 5141944
    Abstract: This invention provides N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides useful for blocking 5HT.sub.2 receptors in mammals having an excess of serotonin centrally or peripherally. The invention also provides methods for treating sexual dysfunction, hypertension, migraine, vasospasm, thrombosis, ischemia, depression, anxiety, sleep disorders and appetite disorders with a compound of the invention.
    Type: Grant
    Filed: June 24, 1991
    Date of Patent: August 25, 1992
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, David W. Robertson
  • N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
    Patent number: 5043341
    Abstract: This invention provides N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides useful for blocking 5HT.sub.2 receptors in mammals having an excess of serotonin centrally or peripherally. The invention also provides methods for treating sexual dysfunction, hypertension, migraine, vasospasm, thrombosis, ischemia, depression, anxiety, sleep disorders and appetite disorders with a compound of the invention.
    Type: Grant
    Filed: April 11, 1990
    Date of Patent: August 27, 1991
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, David W. Robertson
  • 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT.sub.3 antagonists
    Patent number: 4921982
    Abstract: This invention provides bicyclic carboxylic esters and amides, their pharmaceutical formulations, and a method for their use in treating migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in mammals.
    Type: Grant
    Filed: June 14, 1989
    Date of Patent: May 1, 1990
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, William B. Lacefield, David W. Robertson
  • Method for selectively blocking 5-HT.sub.2 receptors
    Patent number: 4914107
    Abstract: This invention relates to the use in vivo of 1-isopropyldihydrolysergic acid as a 5-HT.sub.2 antagonist.
    Type: Grant
    Filed: January 17, 1989
    Date of Patent: April 3, 1990
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, Mark J. Goldberg, Louis Lemberger